MEDI 6012

Drug Profile

MEDI 6012

Alternative Names: ACP-501; MEDI-6012; recombinant-lecithin-cholesterol-acyltransferase; rhLCAT

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AlphaCore Pharma
  • Developer AstraZeneca; MedImmune
  • Class Acyltransferases; Antianaemics; Antihyperlipidaemics; Cardiovascular therapies; Enzymes; Recombinant proteins
  • Mechanism of Action Apolipoprotein A I stimulants; Cholesterol modulators; Transferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lecithin acyltransferase deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes; Atherosclerosis; Coronary artery disease
  • Phase I Arterial thrombosis
  • Preclinical Adrenal gland disorders; Anaemia; Lecithin acyltransferase deficiency; Sickle cell anaemia

Most Recent Events

  • 11 Nov 2017 Adverse events and pharmacodynamics data from a phase IIa trial in Coronary artery disease presented at 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 11 Nov 2017 Pharmacodynamics data from a clinical trial in Coronary artery disease presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 02 Nov 2017 MedImmune completes a phase IIa trial for Atherosclerosis (In the elderly) in USA (IV) (NCT03004638)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top